High Fat Formula With Vitamins, Minerals And Trace Elements And Low In Protein And Carbohydrate
Management of a ketogenic diet in patients requiring high fat formula with low protein and carbohydrate content supplemented with vitamins, minerals and trace elements.
Decisions on record
- Meeting Mar 2023 Recommended Ketogenic diet
- Meeting Jul 2021 Recommended Ketogenic diet
- Meeting Mar 2021 Recommended Ketogenic diet management conditions
- Meeting Mar 2021 Recommended Ketogenic diet
Access path
- Nov 2015Recommended
- Nov 2020Recommended · restricted
Evidence: Other → Single-arm
- Mar 2021Recommended
Comparator changed: KetoCal 4:1, KetoCal 3:1, KetoCal 4:1 LQ → KetoCal 4:1 LQ RTF
- Mar 2021Recommended · restricted
Comparator changed: KetoCal 4:1, KetoCal 3:1, KetoCal 4:1 LQ → KetoCal 4:1 LQ RTF
- Jul 2021Recommended · restricted
Listing: Restricted → Authority Required
- Mar 2023Recommended
Listing: Authority Required → Restricted
- PBS listing · Restricted
From the public summary
6.1 The PBAC recommended that new formulations of high fat formula with vitamins, minerals and trace elements and low in protein and carbohydrate (KetoVie® 3:1, KetoVie® 4:1, KetoVie® Peptide 4:1) continue to be listed on the PBS under the existing conditions of the current formulations.PSD · Mar 2023
6.2 The PBAC noted and supported the NPWP advice that the new formulations are expected to provide a non-inferior clinical benefit for the management of a ketogenic diet.PSD · Mar 2023
5.16 The minor submission presented a cost-minimisation analysis of KetoVie 3:1 and 4:1 compared with KetoCal products based on the same price per kilojoule of $0.0042 at the AEMP. The equi-effective doses were estimated as the same number of kilojoules per day and the comparison was based on the estimated requirement of 6280 kilojoules per day.PSD · Nov 2020
5.17 The sponsor requested a '''''''% premium price for KetoVie Peptide 4:1 over KetoCal 4:1 with an AEMP of $''''''''''''' per kJ (further details on the price are provided in Table 6). The sponsor argued that the premium price was based on: 9PSD · Nov 2020
5.3 The submission claimed non-inferior comparative effectiveness and safety of KetoVie Peptide 4:1 compared with Formulation 1 and Formulation 2. Product cost/patient/year: $'''''''''''''''''PSD · Jul 2021
5.4 The estimated product cost/patient/year would be $''''''''''''''''''' based on 12 prescriptions per year at the AEMP of $''''''''''''. The actual cost will vary due to variations in individual patient needs. Estimated PBS utilisation and financial implicationsPSD · Jul 2021
• The amount of Vitamin A has been lowered to match the levels in KetoVie 4:1 as previous clinician feedback reported some patients on higher calorie volumes approached upper limits of Vitamin A.PSD · Mar 2023
• The amount of Vitamin A has been lowered in the KetoVie 4:1 flavours reformulation to match the levels in KetoVie 4:1 unflavoured as clinician feedback reported some patients on higher calorie volumes approached upper limits of Vitamin A.PSD · Mar 2023
Cost-effectiveness
No economic evaluation conducted; cost-minimisation submission with no change to pricing.
The submission did not present economic or financial evaluations. PSD · 2023
Decision context
PopulationPatients requiring management of a ketogenic diet with high fat formula, low in protein and carbohydrate, supplemented with vitamins, minerals and trace elements.
Submission history
| Decided | Outcome | Comparator | ICER | Evidence |
|---|---|---|---|---|
| Mar 2023 | Recommended | — | — | Cost-minimisation · Cost-minimisation |
| Jul 2021 | Recommended · restricted | KetoCal 4:1; modular amino acid-based formulations (Formulation 1 and Formulation 2) | — | Cost-minimisation · Cost-minimisation |
| Mar 2021 | Recommended | KetoCal 4:1 LQ RTF | — | Cost-minimisation · Cost-minimisation |
| Mar 2021 | Recommended · restricted | — | — | Cost-minimisation |
| Nov 2020 | Recommended · restricted | KetoCal 4:1, KetoCal 3:1, KetoCal 4:1 LQ | — | Single-arm · Seizure frequency |
| Nov 2015 | Recommended | — | — | Other |
Consumer voice
No consumer comments were received for this submission.
The PBAC noted that this item received no consumer comments. Consumer comments · PSD